Idexx Laboratories Inc

Company facts

Industry

In Vitro & In Vivo Diagnostic Substances

Headquarters

Westbrook, Maine

Most recent report

10-Q, filed Aug 4, 2026

Incorporated

Delaware

Filings on record

1,001+ filings

On EDGAR

CIK 874716

Fiscal year ends

December

Filer status

Large accelerated filer

What to read: Jun 2026 10-Q

SECSift found 1 of 11 sections worth reading, with 0 positive, 2 notable, and 0 negative flags.

• Management's Discussion (Item 2)

  Full MD&A with segment revenue, margins, cash flow, debt maturity details, essential for understanding Q2 2026 performance.
  Notable

  • G&A expense includes ~$9M prior-period litigation reduction and a $5M equity investment impairment (both in H1 2026).
  • $75M senior notes due Sept 2026, $75M 2027 Series B notes due Feb 2027; expects to fund with cash/credit/refinancing.

What changed: Jun 2026 vs. Mar 2026

About 14% of IDXX's Jun 2026 10-Q is new information. 42 paragraphs were added, 138 changed, and 25 removed. Below are the most important lines SECSift identified.

• Item 2 66
• Item 1 52
• Item 3 4
• Item 4 2
• Item 5 1
• Item 6 1